Vaccines, blood, antisera, toxins and cultures in   Belgium

Exports In 2023, Belgium exported $28.1B in Vaccines, blood, antisera, toxins and cultures, making it the 5th largest exporter of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 3rd most exported product in Belgium. The main destination of Vaccines, blood, antisera, toxins and cultures exports from Belgium are: United States ($5.13B), Germany ($4.24B), France ($2.31B), Italy ($2.13B), and Japan ($1.37B).

The fastest growing export markets for Vaccines, blood, antisera, toxins and cultures of Belgium between 2022 and 2023 were China ($444M), Netherlands ($160M), and Brunei ($113M).

Imports In 2023, Belgium imported $26.3B in Vaccines, blood, antisera, toxins and cultures, becoming the 3rd largest importer of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 3rd most imported product in Belgium. Belgium imports Vaccines, blood, antisera, toxins and cultures primarily from: Ireland ($7.57B), United States ($6.91B), Switzerland ($5.75B), France ($1.42B), and Germany ($1.27B).

The fastest growing import markets in Vaccines, blood, antisera, toxins and cultures for Belgium between 2022 and 2023 were United States ($4.4B), Switzerland ($1.69B), and Spain ($893M).